Companie

Dr Reddy’s launches generic version of Sabril tablets in US

Our Burea Hyderabad | Updated on February 02, 2021 Published on February 02, 2021

Will have180-day Competitive Generic Therapy exclusivity to market the product

Dr Reddy’s Laboratories Ltd has launched Vigabatrin Tablets, a therapeutic equivalent generic version of Sabril (vigabatrin) tablets approved by the US Food and Drug Administration (USFDA).

“We are pleased that this product has been designated as a Competitive Generic Therapy (CGT) by the FDA,” Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddy’s Laboratories, said in a release on Tuesday.

“With a CGT designation, we have 180-day CGT exclusivity to market this product,” he added.

The Sabril brand and generic had US sales of approximately $141 million MAT for the most recent 12 months ending in December 2020, according to IMS Health.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 02, 2021
preventive medicine
Dr Reddys Laboratories Ltd
US
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.